High-Capacity Poly(2-oxazoline) Formulation of TLR 7/8 Agonist Extends Survival in a Chemo-Insensitive, Metastatic Model of Lung Adenocarcinoma

Researchers showed that their unique poly(2-oxazoline)–based nanomicellar formulation of Resiquimod, an imidazoquinoline Toll-like receptor 7/8 agonist, had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti–PD-1 therapy or platinum-based chemotherapy.